NITROGEN-CONTAINING COMPOUND, COMPOSITION COMPRISING SAID NITROGEN-CONTAINING COMPOUND, AND MARKER FOR PREDICTING TUMOR GRADE - KANSAI MEDICAL UNIV EDUCATIONAL CORPORATION

Title:

NITROGEN-CONTAINING COMPOUND, COMPOSITION COMPRISING SAID NITROGEN-CONTAINING COMPOUND, AND MARKER FOR PREDICTING TUMOR GRADE

Document Type and Number:

WIPO Patent Application WO/2022/210524

Kind Code:

A1

Abstract:

The present invention addresses the problem of providing a nitrogen-containing compound effective for inhibiting cancer stem cell proliferation.　This problem is solved by a nitrogen-containing compound represented by general formula (I) or a pharmaceutically acceptable salt thereof (wherein: m, n and p are the same or different and represent an integer of 1-3; R1, R2 and R3 are the same or different and represent a hydrogen atom, a C1-6 linear or branched alkyl group optionally having a halogen atom as a substituent, a C1-6 linear or branched alkoxy group, a halogen atom, an amino group, a hydroxyl group, a nitro group, a carboxy group or a cyano group; and R4 represents a C1-6 branched or linear alkyl group optionally having a halogen atom as a substituent).

More Like This:

JP2021107425	SUBSTITUTED 1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVE USEFUL IN TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
JP2023523438	substituted heterocyclic compounds
JP2003531934	INDUSTRIAL APPLICABILITY: A catalyst containing an N-pyrrolill-substituted nitrogen donor.

Inventors:

HAYASHI MIKIO (JP)
IKEDA YOSHIKI (JP)
IWATA RYOICHI (JP)

Application Number:

PCT/JP2022/014962

Publication Date:

October 06, 2022

Filing Date:

March 28, 2022

Export Citation:

Click for automatic bibliography generation Help

Assignee:

KANSAI MEDICAL UNIV EDUCATIONAL CORPORATION (JP)

International Classes:

C07D401/14; A61K31/444; A61P35/00; A61P35/04; A61P43/00

Foreign References:

JP2017510291A	2017-04-13
US20090285772A1	2009-11-19

Other References:

MIN ZHANG, ZHEN WANG, YONGQIANG ZHANG, WENXING GUO, HAITAO JI: "Structure-Based Optimization of Small-Molecule Inhibitors for the β-Catenin/B-Cell Lymphoma 9 Protein–Protein Interaction", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 61, no. 7, 12 April 2018 (2018-04-12), US , pages 2989 - 3007, XP055617676, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b00068

Attorney, Agent or Firm:

SAEGUSA & PARTNERS (JP)

Download PDF:

View/Download PDF PDF Help

Previous Patent: FUEL-CELL SECONDARY-USE DETERMINATION SYSTEM AND FUEL-CELL SECONDARY-USE DETERMINATION METHOD

Next Patent: WASTE WATER TREATMENT SYSTEM